ÂÜÀòÂÒÂ×

Julie Jacobs is a Principal Scientist at argenx, with a career that includes roles as Senior Clinical Scientist and Scientist since December 2019. Prior to joining argenx, Julie served as a Postdoctoral Research Fellow at Universiteit Antwerpen from February 2013 to December 2019, where supervision of six PhD students and involvement in translational research on CD70-targeting therapy for colorectal cancer were key responsibilities. Julie's academic background includes a PhD focused on the immunotherapeutic potential of CD70 in solid malignancies, with a thesis available at the Universiteit Antwerpen repository. Earlier experience encompasses research roles at UZA and UZ Gent, where Julie contributed to immunology research while completing a Master in Biomedical Science, specializing in Immunology, at Ghent University.